文献速递类风湿关节炎

甲氨蝶呤通过A20依赖的交叉耐受机制限制炎症

Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism.
PubMed 文献 · Ann Rheum Dis · 2018-02-03

研究探索甲氨蝶呤(MTX)抗炎作用的分子基础,在长期低剂量MTX暴露的人巨噬细胞中检测TLR、RASF和TNFR信号,并在接受MTX单药治疗的关节炎患者及小鼠脓毒症模型中评估MTX体内作用。结果显示MTX使巨噬细胞趋向耐受状态,减少IL-6和IL-1β产生,该效应依赖A20(TNFAIP3),MTX应答者外周血细胞TNFAIP3表达显著更高。

要点

  • MTX使GM-CSF诱导的巨噬细胞趋向耐受状态,减少LPS、LTA、TNFα或RASF刺激下的IL-6和IL-1β产生。
  • MTX诱导的巨噬细胞耐受依赖A20,siRNA敲低A20可逆转MTX对IL-6表达的降低。
  • MTX单药治疗应答者外周血细胞TNFAIP3表达显著更高,A20可能作为MTX应答生物标志物。

核心结论

  • MTX通过上调A20表达损害巨噬细胞促炎反应,A20介导的先天耐受可能限制RA滑膜炎症,并提示A20作为潜在MTX应答生物标志物。

研究设计与样本

  • 体外研究采用长期低剂量MTX暴露的人巨噬细胞,通过定量实时PCR、western blot、ELISA和siRNA介导的敲低方法检测TLR配体、TNFα或RASF刺激的细胞内反应。
  • 体内研究在接受MTX单药治疗的关节炎患者和小鼠脓毒症模型中评估MTX的作用。

主要发现

  • MTX使巨噬细胞趋向耐受状态,减少LPS、LTA、TNFα或RASF刺激下IL-6和IL-1β的产生。
  • MTX减弱LPS诱导的MAPK和NF-κB活化以及TRIF1依赖信号。
  • MTX增加NF-κB抑制因子A20(TNFAIP3)的表达。
  • siRNA介导的A20敲低逆转MTX诱导的IL-6表达降低,表明MTX诱导的巨噬细胞耐受依赖A20。
  • 在MTX单药治疗的关节炎患者队列中,MTX应答者外周血细胞TNFAIP3表达显著更高;MTX治疗小鼠对LPS的炎症反应降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Methotrexate (MTX) is the anchor drug for treatment of rheumatoid arthritis (RA), but the mechanism of its anti-inflammatory action is not fully understood. In RA, macrophages display a proinflammatory polarisation profile that resembles granulocyte-macrophage colony-stimulating factor (GM-CSF)-differentiated macrophages and the response to MTX is only observed in thymidylate synthase+ GM-CSF-dependent macrophages. To determine the molecular basis for the MTX anti-inflammatory action, we explored toll-like receptor (TLR), RA synovial fluid (RASF) and tumour necrosis factor receptor (TNFR)-initiated signalling in MTX-exposed GM-CSF-primed macrophages. METHODS: Intracellular responses to TLR ligands, TNFα or RASF stimulation in long-term low-dose MTX-exposed human macrophages were determined through quantitative real-time PCR, western blot, ELISA and siRNA-mediated knockdown approaches. The role of MTX in vivo was assessed in patients with arthritis under MTX monotherapy and in a murine sepsis model. RESULTS: MTX conditioned macrophages towards a tolerant state, diminishing interleukin (IL)-6 and IL-1β production in LPS, LTA, TNFα or RASF-challenged macrophages. MTX attenuated LPS-induced MAPK and NF-κB activation, and toll/IL-1R domain-containing adaptor inducing IFN-beta (TRIF1)-dependent signalling. Conversely, MTX increased the expression of the NF-κB suppressor A20 (TNFAIP3), itself a RA-susceptibility gene. Mechanistically, MTX-induced macrophage tolerance was dependent on A20, as siRNA-mediated knockdown of A20 reversed the MTX-induced reduction of IL-6 expression. In vivo, TNFAIP3 expression was significantly higher in peripheral blood cells of MTX-responsive individuals from a cohort of patients with arthritis under MTX monotherapy, whereas MTX-treated mice exhibited reduced inflammatory responses to LPS. CONCLUSIONS: MTX impairs macrophage proinflammatory responses through upregulation of A20 expression. The A20-mediated MTX-induced innate tolerance might limit inflammation in the RA synovial context, and positions A20 as a potential MTX-response biomarker.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Municio C, Dominguez-Soto Á, Fuentelsaz-Romero S, et al. Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism. Ann Rheum Dis. 2018. PMID: 29431121. doi:10.1136/annrheumdis-2017-212537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。